IL1B and neoplasm: We propose that targeting IL1β independently or in combination with CXCR2, could be more favorable at earlier stages, where it may hinder the progression of neutrophils toward the tumor-specific subtype, permitting re-education of neutrophils to a tumor-killing phenotype, in addition to permitting an opportunity for other tumor-directed therapies.